4
Changes in Ownership
Candel Therapeutics, Inc. Filed Acc 0000950170-25-042726
Chief Scientific Officer sold 32,146 shares at $8.76 ($281,673)
- Chief Scientific Officer acquired 18,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Barone Francesca Chief Scientific Officer | 2025-03-18 | Option exercise 10b5-1 | +18,000 | $1.55 | $27,900 | 128,673 | D: show line 1 in the form |
| Barone Francesca Chief Scientific Officer | 2025-03-18 | Sale 10b5-1 | −32,146 | $8.76 | $281,673 | 96,527 | D: show line 2 in the form |
| Open-market sales · 32,146 sh · avg $8.76 · $281,673 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Barone Francesca Chief Scientific Officer | 2025-03-18 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,000 | 30,822 | D: show line 3 in the form |
Loading xslF345X05/ownership.xml…